542 related articles for article (PubMed ID: 26262587)
21. Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells.
Fitzgerald TL; Lertpiriyapong K; Cocco L; Martelli AM; Libra M; Candido S; Montalto G; Cervello M; Steelman L; Abrams SL; McCubrey JA
Adv Biol Regul; 2015 Sep; 59():65-81. PubMed ID: 26257206
[TBL] [Abstract][Full Text] [Related]
22. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
Gysin S; Lee SH; Dean NM; McMahon M
Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
[TBL] [Abstract][Full Text] [Related]
23. K-RAS(V12) induces autocrine production of EGFR ligands and mediates radioresistance through EGFR-dependent Akt signaling and activation of DNA-PKcs.
Minjgee M; Toulany M; Kehlbach R; Giehl K; Rodemann HP
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1506-14. PubMed ID: 21985943
[TBL] [Abstract][Full Text] [Related]
24. Evidence that basal activity, but not transactivation, of the epidermal growth factor receptor tyrosine kinase is required for insulin-like growth factor I-induced activation of extracellular signal-regulated kinase in oral carcinoma cells.
Kuribayashi A; Kataoka K; Kurabayashi T; Miura M
Endocrinology; 2004 Nov; 145(11):4976-84. PubMed ID: 15271882
[TBL] [Abstract][Full Text] [Related]
25. Role of Runx2 in crosstalk between Mek/Erk and PI3K/Akt signaling in MCF-10A cells.
Tandon M; Chen Z; Pratap J
J Cell Biochem; 2014 Dec; 115(12):2208-17. PubMed ID: 25147082
[TBL] [Abstract][Full Text] [Related]
26. VRK2 inhibits mitogen-activated protein kinase signaling and inversely correlates with ErbB2 in human breast cancer.
Fernández IF; Blanco S; Lozano J; Lazo PA
Mol Cell Biol; 2010 Oct; 30(19):4687-97. PubMed ID: 20679487
[TBL] [Abstract][Full Text] [Related]
27. Parallel signaling pathways in endothelin-1-induced proliferation of U373MG astrocytoma cells.
He S; Dibas A; Yorio T; Prasanna G
Exp Biol Med (Maywood); 2007 Mar; 232(3):370-84. PubMed ID: 17327470
[TBL] [Abstract][Full Text] [Related]
28. Multiple mitogenic pathways in pancreatic cancer cells are blocked by a truncated epidermal growth factor receptor.
Matsuda K; Idezawa T; You XJ; Kothari NH; Fan H; Korc M
Cancer Res; 2002 Oct; 62(19):5611-7. PubMed ID: 12359775
[TBL] [Abstract][Full Text] [Related]
29. Signal transduction of MEK/ERK and PI3K/Akt activation by hypoxia/reoxygenation in renal epithelial cells.
Kwon DS; Kwon CH; Kim JH; Woo JS; Jung JS; Kim YK
Eur J Cell Biol; 2006 Nov; 85(11):1189-99. PubMed ID: 16860436
[TBL] [Abstract][Full Text] [Related]
30. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
31. Type II cGMP-dependent protein kinase inhibits EGF-triggered signal transduction of the MAPK/ERK-mediated pathway in gastric cancer cells.
Wu Y; Chen Y; Qu R; Lan T; Sang J
Oncol Rep; 2012 Feb; 27(2):553-8. PubMed ID: 22012247
[TBL] [Abstract][Full Text] [Related]
32. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
33. Growth hormone alters epidermal growth factor receptor binding affinity via activation of extracellular signal-regulated kinases in 3T3-F442A cells.
Huang Y; Chang Y; Wang X; Jiang J; Frank SJ
Endocrinology; 2004 Jul; 145(7):3297-306. PubMed ID: 15070853
[TBL] [Abstract][Full Text] [Related]
34. EGF‑stimulated AKT activation is mediated by EGFR recycling via an early endocytic pathway in a gefitinib‑resistant human lung cancer cell line.
Nishimura Y; Takiguchi S; Ito S; Itoh K
Int J Oncol; 2015 Apr; 46(4):1721-9. PubMed ID: 25653196
[TBL] [Abstract][Full Text] [Related]
35. EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients.
Tzeng CW; Frolov A; Frolova N; Jhala NC; Howard JH; Vickers SM; Buchsbaum DJ; Heslin MJ; Arnoletti JP
J Surg Res; 2007 Nov; 143(1):20-6. PubMed ID: 17950068
[TBL] [Abstract][Full Text] [Related]
36. Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor.
Ozaki N; Ohmuraya M; Hirota M; Ida S; Wang J; Takamori H; Higashiyama S; Baba H; Yamamura K
Mol Cancer Res; 2009 Sep; 7(9):1572-81. PubMed ID: 19737965
[TBL] [Abstract][Full Text] [Related]
37. Neurotensin stimulates protein kinase C-dependent mitogenic signaling in human pancreatic carcinoma cell line PANC-1.
Guha S; Lunn JA; Santiskulvong C; Rozengurt E
Cancer Res; 2003 May; 63(10):2379-87. PubMed ID: 12750255
[TBL] [Abstract][Full Text] [Related]
38. Tanshinone IIA can inhibit MiaPaCa‑2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways.
Su CC
Oncol Rep; 2018 Nov; 40(5):3102-3111. PubMed ID: 30226540
[TBL] [Abstract][Full Text] [Related]
39. Transforming growth factor β and Ras/MEK/ERK signaling regulate the expression level of a novel tumor suppressor Lefty.
Miyata N; Azuma T; Hozawa S; Higuchi H; Yokoyama A; Kabashima A; Igarashi T; Saeki K; Hibi T
Pancreas; 2012 Jul; 41(5):745-52. PubMed ID: 22441145
[TBL] [Abstract][Full Text] [Related]
40. Role of somatostatin receptor 1 and 5 on epidermal growth factor receptor mediated signaling.
Kharmate G; Rajput PS; Watt HL; Somvanshi RK; Chaudhari N; Qiu X; Kumar U
Biochim Biophys Acta; 2011 Jun; 1813(6):1172-89. PubMed ID: 21419811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
